Better Health for All

Cocrystal Pharma's core business is the development of antiviral therapeutics for major global health issues such as influenza, norovirus, and coronaviruses, which cause millions of cases, hospitalizations, and deaths annually.

Their entire business is devoted to health improvement through drug development, with 100% of their portfolio focused on these areas. The company has reported favorable safety and tolerability profiles for its lead candidates, CC-42344 and CDI-988, in multiple Phase 1 and Phase 2a studies, with no serious adverse events or drug-related discontinuations. The company's products are designed to address significant health burdens, including norovirus, which causes 1.1 million hospitalizations and 218,000 deaths annually in children in the developing world. Cocrystal Pharma employs a structure-based drug discovery platform and Nobel Prize-winning expertise, with R&D expenses of $12.5 million in 2024 and $12.392 million in 2022, representing 100% of its operational focus on health innovation. The company is actively developing products for both prevention and treatment, with CDI-988 being evaluated as a potential norovirus preventive and treatment, and CC-42344 for prophylaxis and treatment of influenza. The company is also developing treatments for global health crises like SARS-CoV-2 and pandemic influenza. Clinical trials are conducted with ethical oversight, including approval from the Australian Human Research Ethics Committee and IRB approval from Emory University. However, the company's press releases consistently include forward-looking statements with cautionary notes about various risks and uncertainties, indicating a moderate level of risk transparency. There is no specific information on patent flexibility or pricing strategies to ensure accessibility for low-income populations.

Fair Pay & Worker Respect

Cocrystal Pharma received an overall employee rating of 4.2 out of 5 on Glassdoor, based on 2 reviews.

This translates to an 84% engagement score. According to the rubric, an engagement score of ~80/100 maps to tier 30, and ~85/100 maps to tier 40. As 84% falls between these two tiers, the tier closer to zero (less extreme) is 30. The company had 11 employees as of December 31, 2024, and 12 employees as of December 31, 2023. The employee count of 11 is too small for meaningful turnover metrics, resulting in a score of N/A (0) for turnover rate. There is no public record of labor-law breaches, resulting in a score of N/A (0) for labor violation incidents.

Honest & Fair Business

No specific, concrete data points were found in the provided articles for any of the KPIs related to Honest & Fair Business. While the company's Code of Ethics is mentioned, and compliance with the FCPA is noted, the articles do not provide sufficient detail or quantitative evidence regarding the strength, enforcement, or specific outcomes of these policies to meet the rubric's scoring criteria.

There is no information on regulatory fines, transparency index scores, specific whistleblower policy details, financial restatements, audit coverage, ESG controversy scores, complaint resolution times, board conflict-free percentages, or third-party verification of ethical claims. Therefore, all KPIs have been omitted due to a lack of explicit evidence.

Kind to Animals

The company and its third-party contractors conduct research using animals for medical analysis and clinical research, including product testing in animal models for influenza drugs.

There is no evidence that any of the company's products are certified cruelty-free. The company states it complies with governmental regulations regarding the treatment of animals used in research, such as the Animal Welfare Act (AWA), but there is no evidence of a policy to reduce or prohibit animal testing beyond basic legal compliance. No operational sites hold any humane certification.

No War, No Weapons

The provided articles, which include financial reports, press releases, and export control lists, focus on Cocrystal Pharma, Inc.'s research and development efforts in antiviral therapeutics and general financial performance. All articles explicitly state that no data relevant to the 'No War, No Weapons' value or the company's activities in this context is present.

Consequently, no specific evidence could be found to assess the company against any of the defined KPIs for this value.

Respect for Cultures & Communities

No specific, concrete data points or information relevant to the ethical value 'Respect for Cultures & Communities' were found across any of the provided articles.

The articles primarily focus on financial results, corporate governance, and research and development updates for antiviral therapeutics, explicitly stating the absence of data pertaining to community engagement, cultural impact, or related metrics.

Safe & Smart Tech

The provided articles do not contain specific, concrete data points for any of the KPIs related to Safe & Smart Tech for Cocrystal Pharma, Inc. (COCP.US). While one article discusses general cybersecurity incidents and data breaches within the pharmaceutical industry, it does not attribute any such incidents or specific security practices to Cocrystal Pharma.

An UpGuard report noted no recent security news or data breaches for Cocrystal Pharma, but this is an absence of reported issues, not affirmative evidence of a perfect security record or specific security measures. The company's privacy policy outlines data collection and states personal information is not shared, but this is a policy statement and not evidence of the absence of unauthorized data use incidents, the effectiveness of preventative measures, or specific user data controls. No information is available regarding AI ethics, cybersecurity investment, privacy certifications, security training, encryption implementation, AI audit practices, algorithmic transparency, authentication security, vulnerability management, bug bounty programs, privacy by design, security testing coverage, data minimization practices, regulatory compliance, algorithmic harm remediation, or digital rights advocacy for Cocrystal Pharma.